Transmyocardial revascularization

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Scripps La Jolla First in U.S. to Use ZOLL’s FDA-approved Supersaturated Oxygen Therapy on Patients Suffering From Widowmaker Heart Attacks

Tuesday, January 14, 2020 - 3:00pm

ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Scripps Memorial Hospital La Jolla, in San Diego, Calif., treated its first widowmaker heart attack patient with SuperSaturated Oxygen (SSO2) Therapy.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Scripps Memorial Hospital La Jolla, in San Diego, Calif., treated its first widowmaker heart attack patient with SuperSaturated Oxygen (SSO2) Therapy.
  • For many patients, even after blood flow is quickly restored with angioplasty and stenting, irreversible damage to the heart muscle may occur.
  • SSO2 Therapy delivers localized superoxygenated blood, with the goal of improving microvascular blood flow and reducing damage to the heart muscle.
  • More than 30% percent of severe heart attack patients develop heart failure,3 and of those, 50% will die within five years.3 SSO2 Therapy has been shown in randomized prospective clinical trials to safely reduce infarct size in widowmaker heart attack patients.